GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » Price-to-Free-Cash-Flow

Landos Biopharma (Landos Biopharma) Price-to-Free-Cash-Flow : N/A (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma Price-to-Free-Cash-Flow?

As of today (2024-05-23), Landos Biopharma's share price is $22.93. Landos Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.35. Hence, Landos Biopharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Landos Biopharma's Price-to-Free-Cash-Flow or its related term are showing as below:

LABP's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.86
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Landos Biopharma's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-1.37. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-3.35.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -13.90% per year.

During the past 6 years, Landos Biopharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 18.00% per year. The lowest was -54.60% per year. And the median was -34.60% per year.


Landos Biopharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Landos Biopharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma Price-to-Free-Cash-Flow Chart

Landos Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Landos Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Landos Biopharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Landos Biopharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Landos Biopharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Landos Biopharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Landos Biopharma's Price-to-Free-Cash-Flow falls into.



Landos Biopharma Price-to-Free-Cash-Flow Calculation

Landos Biopharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=22.93/-3.352
=N/A

Landos Biopharma's Share Price of today is $22.93.
Landos Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Landos Biopharma  (NAS:LABP) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Landos Biopharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Landos Biopharma (Landos Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 11239, Blacksburg, VA, USA, 24060
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.
Executives
Alka Batycky director C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi officer: Chief Medical Officer C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes director, officer: Chief Executive Officer 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell officer: Vice President and Controller C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera director, 10 percent owner, officer: Chairman, President and CEO 1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar officer: Interim CFO C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003